Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 8/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | TYMS | P04818 | 1/20 | 0.45 |
| ▸ | NFKBIA | P25963 | 2/20 | 0.43 |
| ▸ | RELA | Q04206 | 2/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998785 | 0.89 | PPARG (0.57) | PPARGCYP3A4MCL1 | |
| SCHEMBL13678547 | 0.89 | FSCN1 (0.45) | FSCN1PPARGCYP3A4MEN1KMT2A | |
| SCHEMBL2003674 | 0.86 | PPARG (0.53) | FSCN1PPARGCYP3A4MEN1KMT2A | |
| SCHEMBL2000864 | 0.82 | PPARG (0.56) | PPARGCYP3A4 | |
| SCHEMBL2000742 | 0.81 | PPARG (0.58) | PPARGCYP3A4 | |
| SCHEMBL1994977 | 0.81 | PPARG (0.53) | FSCN1PPARGCYP3A4TYMSMEN1 | |
| SCHEMBL2000451 | 0.81 | PPARG (0.54) | PPARGCYP3A4MEN1KMT2ANPC1 | |
| SCHEMBL2000098 | 0.79 | PPARG (0.56) | PPARGCYP3A4MEN1KMT2AKDR | |
| SCHEMBL2004408 | 0.79 | PPARG (0.56) | PPARGCYP3A4NPC1 | |
| SCHEMBL1999074 | 0.79 | PPARG (0.56) | PPARGCYP3A4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960408-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960408-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960408-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7601841-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. (US) | 2009-09-03 | — | — | US | disclosed |
| EP-1296967-B1 | BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | AMGEN INC (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20040176409-A1 | Quinolinyl and benzothiazolyl modulators | TULARIK INC | 2004-09-09 | — | — | US | disclosed |
| US-20030171399-A1 | Quinolinyl and benzothiazolyl modulators | TULARIK INC. | 2003-09-11 | — | — | US | disclosed |
| US-6583157-B2 | Peroxisome proliferator-activated receptors antagonists; antiinflammatory agents and treating metabolic disorders | TULARIK INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1296967-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | Tularik Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002000633-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176409-A1 | Quinolinyl and benzothiazolyl modulators | PPARA, PPARG, PPARD | FSCN1 4835/4885PPARG 2/4885CYP3A4 675/4885 |
| US-20030171399-A1 | Quinolinyl and benzothiazolyl modulators | PPARA, PPARG, PPARD | FSCN1 4835/4885PPARG 2/4885CYP3A4 675/4885 |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARA, PPARG, PPARD | FSCN1 4835/4885PPARG 2/4885CYP3A4 675/4885 |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARG, PPARA, PPARD | FSCN1 4826/4885PPARG 1/4885CYP3A4 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.